5-BROMO-2-(4-BROMO-3,5-DIMETHYL-1H-PYRAZOL-1-YL)-6-METHYLPYRIMIDIN-4-OL


Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	XSRALKWKAAJACR-UHFFFAOYSA-N
Smiles	Cc1nc(nc(O)c1Br)n2nc(C)c(Br)c2C
InChI	InChI=1S/C10H10Br2N4O/c1-4-8(12)9(17)14-10(13-4)16-6(3)7(11)5(2)15-16/h1-3H3,(H,13,14,17)

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C10H10Br2N4O
Molecular Weight	362.02
AlogP	3.3
Hydrogen Bond Acceptor	4.0
Hydrogen Bond Donor	1.0
Number of Rotational Bond	1.0
Polar Surface Area	63.83
Molecular species	ACID
Aromatic Rings	2.0
Heavy Atoms	17.0

Assay Description	Organism	Bioactivity
Fungicidal activity against Magnaporthe oryzae in rice seedlings assessed as control of rice blast at 500 ppm by preventive foliar treatment	Magnaporthe oryzae	40.0 %
Fungicidal activity against Magnaporthe oryzae in rice seedlings assessed as control of rice blast at 500 ppm by curative foliar treatment	Magnaporthe oryzae	31.0 %
Fungicidal activity against Magnaporthe oryzae by agar dilution method	Magnaporthe oryzae	50.0 ug.mL-1
Fungicidal activity against Magnaporthe salvinii by agar dilution method	Magnaporthe salvinii	25.0 ug.mL-1

Cross References

Resources	Reference
ChEMBL	CHEMBL2288260
PubChem	76331102

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).